ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

NVUS Novus Therapeutics Inc

14.60
0.00 (0.00%)
26 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Novus Therapeutics Inc NASDAQ:NVUS NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 14.60 14.65 21.00 0 01:00:00

TKAI INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Tokai Pharmaceuticals, Inc...

13/09/2016 6:36pm

Business Wire


Novus Therapeutics (NASDAQ:NVUS)
Historical Stock Chart


From Apr 2019 to Apr 2024

Click Here for more Novus Therapeutics Charts.

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased Tokai Pharmaceuticals, Inc. (NASDAQGM: TKAI) securities between June 24, 2015 and July 25, 2016.

Click here to learn about the case: http://www.wongesq.com/pslra/tokai-pharmaceuticals-inc. There is no cost or obligation to you.

According to the complaint, throughout the Class Period, Defendants issued false and/or misleading statements to investors and/or failed to disclose that: (1) there were noteworthy structural problems with ARMOR3-SV, the trial design for Tokai's pivotal Phase 3 Galeterone study, (2) accordingly, ARMOR3-SV would probably not meet its primary endpoint; (3) therefore, the likelihood of Galeterone's commercialization was not as probable as Tokai had told investors; and (4) consequently, Tokai's financial statements were false and misleading and/or lacked a reasonable basis.

Additionally, on July 26, 2016, Tokai announced it would end a late-stage trial of Galeterone, saying it believed the stage 3 study would not meet its primary endpoint. Following this news, Tokai shares fell from $5.20 on July 25, 2016, to a close of $1.10 on July 26, 2016.

If you suffered a loss in Tokai you have until September 30, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email vw@wongesq.com, by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/tokai-pharmaceuticals-inc.

Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

The Law Offices of Vincent WongVincent Wong, Esq., 212-425-1140Fax. 866-699-3880vw@wongesq.com

1 Year Novus Therapeutics Chart

1 Year Novus Therapeutics Chart

1 Month Novus Therapeutics Chart

1 Month Novus Therapeutics Chart

Your Recent History

Delayed Upgrade Clock